248 related articles for article (PubMed ID: 23596295)
21. Removal of the C6 Vaccinia Virus Interferon-β Inhibitor in the Hepatitis C Vaccine Candidate MVA-HCV Elicited in Mice High Immunogenicity in Spite of Reduced Host Gene Expression.
Marín MQ; Pérez P; Gómez CE; Sorzano CÓS; Esteban M; García-Arriaza J
Viruses; 2018 Aug; 10(8):. PubMed ID: 30096846
[TBL] [Abstract][Full Text] [Related]
22. Spontaneous and Targeted Mutations in the Decapping Enzyme Enhance Replication of Modified Vaccinia Virus Ankara (MVA) in Monkey Cells.
Erez N; Wyatt LS; Americo JL; Xiao W; Moss B
J Virol; 2021 Sep; 95(19):e0110421. PubMed ID: 34232734
[TBL] [Abstract][Full Text] [Related]
23. Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens.
Braxton CL; Puckett SH; Mizel SB; Lyles DS
J Virol; 2010 Apr; 84(7):3552-61. PubMed ID: 20089648
[TBL] [Abstract][Full Text] [Related]
24. Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against Leishmania.
Dondji B; Deak E; Goldsmith-Pestana K; Perez-Jimenez E; Esteban M; Miyake S; Yamamura T; McMahon-Pratt D
Eur J Immunol; 2008 Mar; 38(3):706-19. PubMed ID: 18286565
[TBL] [Abstract][Full Text] [Related]
25. The Virulence of Different Vaccinia Virus Strains Is Directly Proportional to Their Ability To Downmodulate Specific Cell-Mediated Immune Compartments
de Freitas LFD; Oliveira RP; Miranda MCG; Rocha RP; Barbosa-Stancioli EF; Faria AMC; da Fonseca FG
J Virol; 2019 Mar; 93(6):. PubMed ID: 30567985
[TBL] [Abstract][Full Text] [Related]
26. Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions.
García-Arriaza J; Nájera JL; Gómez CE; Sorzano CO; Esteban M
PLoS One; 2010 Aug; 5(8):e12395. PubMed ID: 20811493
[TBL] [Abstract][Full Text] [Related]
27. Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes.
Gherardi MM; Nájera JL; Pérez-Jiménez E; Guerra S; García-Sastre A; Esteban M
J Virol; 2003 Jun; 77(12):7048-57. PubMed ID: 12768024
[TBL] [Abstract][Full Text] [Related]
28. Characterizing the effects of insertion of a 5.2 kb region of a VACV genome, which contains known immune evasion genes, on MVA immunogenicity.
Ryerson MR; Shisler JL
Virus Res; 2018 Feb; 246():55-64. PubMed ID: 29341877
[TBL] [Abstract][Full Text] [Related]
29. A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees.
Schneider J; Langermans JA; Gilbert SC; Blanchard TJ; Twigg S; Naitza S; Hannan CM; Aidoo M; Crisanti A; Robson KJ; Smith GL; Hill AV; Thomas AW
Vaccine; 2001 Sep; 19(32):4595-602. PubMed ID: 11535306
[TBL] [Abstract][Full Text] [Related]
30. Introduction of the six major genomic deletions of modified vaccinia virus Ankara (MVA) into the parental vaccinia virus is not sufficient to reproduce an MVA-like phenotype in cell culture and in mice.
Meisinger-Henschel C; Späth M; Lukassen S; Wolferstätter M; Kachelriess H; Baur K; Dirmeier U; Wagner M; Chaplin P; Suter M; Hausmann J
J Virol; 2010 Oct; 84(19):9907-19. PubMed ID: 20668072
[TBL] [Abstract][Full Text] [Related]
31. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
J Virol; 2017 May; 91(9):. PubMed ID: 28179536
[TBL] [Abstract][Full Text] [Related]
32. A novel naturally occurring tandem promoter in modified vaccinia virus ankara drives very early gene expression and potent immune responses.
Wennier ST; Brinkmann K; Steinhäußer C; Mayländer N; Mnich C; Wielert U; Dirmeier U; Hausmann J; Chaplin P; Steigerwald R
PLoS One; 2013; 8(8):e73511. PubMed ID: 23951355
[TBL] [Abstract][Full Text] [Related]
33. Modified Vaccinia virus Ankara: innate immune activation and induction of cellular signalling.
Price PJ; Torres-Domínguez LE; Brandmüller C; Sutter G; Lehmann MH
Vaccine; 2013 Sep; 31(39):4231-4. PubMed ID: 23523404
[TBL] [Abstract][Full Text] [Related]
34. Enhanced CD8+ T cell immune response against a V3 loop multi-epitope polypeptide (TAB13) of HIV-1 Env after priming with purified fusion protein and booster with modified vaccinia virus Ankara (MVA-TAB) recombinant: a comparison of humoral and cellular immune responses with the vaccinia virus Western Reserve (WR) vector.
Gómez CE; Rodríguez D; Rodríguez JR; Abaitua F; Duarte C; Esteban M
Vaccine; 2001 Dec; 20(5-6):961-71. PubMed ID: 11738764
[TBL] [Abstract][Full Text] [Related]
35. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
36. SPI-1 is a missing host-range factor required for replication of the attenuated modified vaccinia Ankara (MVA) vaccine vector in human cells.
Liu R; Mendez-Rios JD; Peng C; Xiao W; Weisberg AS; Wyatt LS; Moss B
PLoS Pathog; 2019 May; 15(5):e1007710. PubMed ID: 31145755
[TBL] [Abstract][Full Text] [Related]
37. Immediate-early expression of a recombinant antigen by modified vaccinia virus ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responses.
Baur K; Brinkmann K; Schweneker M; Pätzold J; Meisinger-Henschel C; Hermann J; Steigerwald R; Chaplin P; Suter M; Hausmann J
J Virol; 2010 Sep; 84(17):8743-52. PubMed ID: 20538860
[TBL] [Abstract][Full Text] [Related]
38. A Vaccine Based on a Modified Vaccinia Virus Ankara Vector Expressing Zika Virus Structural Proteins Controls Zika Virus Replication in Mice.
Pérez P; Q Marín M; Lázaro-Frías A; Jiménez de Oya N; Blázquez AB; Escribano-Romero E; S Sorzano CÓ; Ortego J; Saiz JC; Esteban M; Martín-Acebes MA; García-Arriaza J
Sci Rep; 2018 Nov; 8(1):17385. PubMed ID: 30478418
[TBL] [Abstract][Full Text] [Related]
39. Protective immune response against cutaneous leishmaniasis by prime/booster immunization regimens with vaccinia virus recombinants expressing Leishmania infantum p36/LACK and IL-12 in combination with purified p36.
Gonzalo RM; Rodríguez JR; Rodríguez D; González-Aseguinolaza G; Larraga V; Esteban M
Microbes Infect; 2001 Jul; 3(9):701-11. PubMed ID: 11489418
[TBL] [Abstract][Full Text] [Related]
40. A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses.
García-Arriaza J; Nájera JL; Gómez CE; Tewabe N; Sorzano CO; Calandra T; Roger T; Esteban M
PLoS One; 2011; 6(8):e24244. PubMed ID: 21909386
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
